Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Retained Earnings (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Retained Earnings for 10 consecutive years, with -$764000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 221.08% year-over-year to -$764000.0, compared with a TTM value of -$764000.0 through Dec 2025, down 221.08%, and an annual FY2025 reading of -$764000.0, down 221.08% over the prior year.
  • Retained Earnings was -$764000.0 for Q4 2025 at Zevra Therapeutics, up from -$434.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $631000.0 in Q4 2024 and bottomed at -$469.6 million in Q3 2024.
  • Average Retained Earnings over 5 years is -$190.3 million, with a median of -$263.4 million recorded in 2021.
  • Peak annual rise in Retained Earnings hit 1567.44% in 2024, while the deepest fall reached 213331.82% in 2024.
  • Year by year, Retained Earnings stood at -$264.3 million in 2021, then crashed by 33.82% to -$353.7 million in 2022, then soared by 99.99% to -$43000.0 in 2023, then soared by 1567.44% to $631000.0 in 2024, then plummeted by 221.08% to -$764000.0 in 2025.
  • Business Quant data shows Retained Earnings for ZVRA at -$764000.0 in Q4 2025, -$434.2 million in Q3 2025, and -$433.7 million in Q2 2025.